Literature DB >> 20824786

Acute airway obstruction in cervical spinal procedures with bone morphogenetic proteins.

Kathleen L Yaremchuk1, Mark S Toma, Melissa L Somers, Ed Peterson.   

Abstract

OBJECTIVES: Bone morphogenetic proteins (BMP) used in anterior cervical spinal procedures causes an inflammatory response resulting in upper-airway obstruction between postoperative days 2 to 7. The purpose of this study is to determine the incidence and severity of complications associated with use of BMP. STUDY
DESIGN: Retrospective cohort study.
METHODS: This is a retrospective study of 260 patients who underwent cervical spinal procedures with BMP from 2004 to 2009 and a control group of 515 patients who underwent cervical spinal procedures without BMP during the same period at a tertiary care institution. The two groups were compared on hospital length of stay (LOS), hospital charges, incidence of airway obstruction, unplanned intubations after surgery, tracheotomies, intensive care unit (ICU) admissions, hoarseness, dyspnea, respiratory failure, dysphasia, dysphagia, readmissions, and need for percutaneous endoscopic gastrostomy (PEG) tubes.
RESULTS: Patients who underwent cervical spine procedures with BMP were noted to have significantly longer hospital stays (P = .001) and higher hospital charges (P = .001) than the control group. Tracheotomies (P = .024), unplanned intubations after surgery (P = .003), dysphagia (P = .001), dyspnea (P = .001), respiratory failure (P = .001), hospital readmissions (P = .040), ICU admissions (P = .001), and 90-day mortality rates (P = .047) were increased for the BMP group.
CONCLUSIONS: The use of BMP in anterior cervical spinal procedures results in acute airway obstruction due to an extensive soft-tissue inflammatory reaction that is most likely to occur 2 to 7 days after surgery. The increased incidence of unplanned intubations and tracheotomies demonstrates the risk associated with BMP in cervical spinal procedures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20824786     DOI: 10.1002/lary.21096

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  13 in total

1.  Cervical spine: degenerative conditions.

Authors:  Andrew G Todd
Journal:  Curr Rev Musculoskelet Med       Date:  2011-12

Review 2.  Biomaterial delivery of morphogens to mimic the natural healing cascade in bone.

Authors:  Manav Mehta; Katharina Schmidt-Bleek; Georg N Duda; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2012-05-22       Impact factor: 15.470

3.  Salicylic Acid-Based Polymers for Guided Bone Regeneration Using Bone Morphogenetic Protein-2.

Authors:  Sangeeta Subramanian; Ashley Mitchell; Weiling Yu; Sabrina Snyder; Kathryn Uhrich; J Patrick O'Connor
Journal:  Tissue Eng Part A       Date:  2015-04-29       Impact factor: 3.845

Review 4.  A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.

Authors:  Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part B Rev       Date:  2016-04-19       Impact factor: 6.389

5.  Pros, cons, and costs of INFUSE in spinal surgery.

Authors:  Nancy E Epstein
Journal:  Surg Neurol Int       Date:  2011-01-24

6.  Off-label use of rhBMP-2.

Authors:  Clark Watts
Journal:  Surg Neurol Int       Date:  2011-03-31

7.  Recombinant human bone morphogenetic protein 2 labeled use in spinal surgery and sexual dysfunction.

Authors:  Marija Rakovac; Ivan Bojanic; Tomislav Smoljanovic
Journal:  Surg Neurol Int       Date:  2011-04-28

8.  Commentary: Bone morphogenetic protein's contribution to pulmonary artery hypertension: Should this raise concern for patients undergoing spinal fusions with bone morphogenetic protein?

Authors:  Nancy E Epstein
Journal:  Surg Neurol Int       Date:  2014-12-30

9.  Testosterone delivered with a scaffold is as effective as bone morphologic protein-2 in promoting the repair of critical-size segmental defect of femoral bone in mice.

Authors:  Bi-Hua Cheng; Tien-Min G Chu; Chawnshang Chang; Hong-Yo Kang; Ko-En Huang
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Bone marrow concentrate promotes bone regeneration with a suboptimal-dose of rhBMP-2.

Authors:  Kazuhiro Egashira; Yoshinori Sumita; Weijian Zhong; Takashi I; Seigo Ohba; Kazuhiro Nagai; Izumi Asahina
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.